Results 141 to 150 of about 4,986,038 (258)
Aims Non‐adherence to oral anticoagulants (OACs) is associated with significant morbidity and mortality. Mobile health (mHealth) interventions have been used to improve medication adherence across the three phases of initiation, implementation and persistence.
Non Davies +2 more
wiley +1 more source
Transcatheter mitral and tricuspid interventions-the bigger picture: valvular disease as part of heart failure. [PDF]
Curio J, Beneduce A, Giannini F.
europepmc +1 more source
Introduction Warfarin therapy is the mainstay of anticoagulation treatment in South Africa and requires frequent INR monitoring due to interindividual patient variability. Time in therapeutic range (TTR) reflects the proportion of total treatment time during which INR values are within therapeutic range.
Masudah Paleker +3 more
wiley +1 more source
Implementation and use of risk minimization control tools in the EU: A multistakeholder survey
Aims This study characterized stakeholders' experiences with national implementation of risk minimization control tools (RMCTs), such as healthcare professional qualification, healthcare facility accreditation and medical intervention prior to treatment initiation, for eight medicinal products across eight European Union countries. Methods We conducted
Sharon C. M. Essink +21 more
wiley +1 more source
The current landscape of lipoprotein(a) in calcific aortic valvular disease. [PDF]
Hsieh G +4 more
europepmc +1 more source
Background Guidelines recommend oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the United States, apixaban is unlicensed for use in patients with end‐stage renal disease (ESRD) receiving renal replacement therapy (RRT).
John K. Bartoli‐Abdou +10 more
wiley +1 more source
Pathophysiology and management of valvular disease in patients with destination left ventricular assist devices. [PDF]
Dimarakis I +6 more
europepmc +1 more source
Genetic Basis of Valvular Heart Disease
Valvular heart disease is a common cause of heart failure. Identification of the genetic causes of valvular heart disease has important implications in our understanding of these heart diseases, as well as translating these genetic discoveries into ...
core
CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien +7 more
wiley +1 more source
Alternative access for transapical transcatheter mitral valve implantationCentral Message
Heinz Deschka, MD +3 more
doaj +1 more source

